Is obstructive sleep apnea the missing link between metabolic syndrome and second-generation antipsychotics:...

Area of Science:

• Psychiatry
• Endocrinology
• Sleep Medicine

Background:

• Metabolic syndrome is a common concern in patients using second-generation antipsychotics.
• Antipsychotic-induced weight gain is the presumed cause, but obstructive sleep apnea (OSA) is an emerging factor.
• This study investigates the role of OSA in antipsychotic-related metabolic syndrome.

Purpose of the Study:

• To explore the contribution of obstructive sleep apnea (OSA) in the development of metabolic syndrome among individuals treated with second-generation antipsychotics.
• To identify potential mediators of metabolic syndrome beyond weight gain in this patient population.

Main Methods:

• Forty-three patients with schizophrenia or major depressive disorder on second-generation antipsychotics were assessed.
• Obstructive sleep apnea (OSA) was screened using the Berlin Questionnaire.
• Metabolic syndrome was diagnosed using the Adult Treatment Panel-III criteria, with fasting glucose and lipid profiles measured.

Main Results:

• 25.6% of participants had metabolic syndrome, and 20.9% were at high risk for OSA.
• Obstructive sleep apnea (OSA) was a significant risk factor for metabolic syndrome (OR = 15.09).
• Increased waist circumference and fasting plasma glucose also elevated metabolic syndrome risk.

Conclusions:

• Obstructive sleep apnea (OSA) plays a significant role in mediating metabolic syndrome in patients using second-generation antipsychotics.
• These findings suggest that screening for and managing OSA may be crucial in this patient group.